Hexanoate

Hexanoate

SCHEMBL149901

CCCCCC(=O)O.[Mg+2]c1ccccc1

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.61
PPARG P37231 8/20 0.59
PPARD Q03181 8/20 0.59
PPARA Q07869 8/20 0.59
GPR84 Q9NQS5 7/20 0.59
HDAC11 Q96DB2 5/20 0.59
TSHR P16473 4/20 0.59
PTPN1 P18031 3/20 0.59
FFAR1 O14842 3/20 0.59
ALDH1A1 P00352 2/20 0.59
TLR2 O60603 2/20 0.59
TDP1 Q9NUW8 2/20 0.59
FABP4 P15090 2/20 0.59
KMT2A Q03164 2/20 0.59
ESR1 P03372 2/20 0.59
SLC22A6 Q4U2R8 1/20 0.59
SLC22A8 Q8TCC7 1/20 0.59
MEN1 O00255 1/20 0.59
ALOX15 P16050 1/20 0.59
PDE4A P27815 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Biphenyl SCHEMBL27337978 0.84 AKR1B1 (0.67) AKR1B1PPARGPPARDPPARAGPR84
Naphthalene SCHEMBL28148380 0.84 AKR1B1 (0.67) AKR1B1PPARGPPARDPPARAGPR84
Hexanoate SCHEMBL9303080 0.83 AKR1B1 (0.89) AKR1B1PPARGPPARDPPARAGPR84
Decanoic Acid SCHEMBL31619443 0.82 GPR84 (0.68) AKR1B1PPARGPPARDPPARAGPR84
Behenic Acid SCHEMBL8855897 0.82 GPR84 (0.68) AKR1B1PPARGPPARDPPARAGPR84
Hexanoate SCHEMBL9352753 0.82 AKR1B1 (0.64) AKR1B1PPARGPPARDPPARAGPR84
Stearic Acid SCHEMBL8855788 0.82 GPR84 (0.68) AKR1B1PPARGPPARDPPARAGPR84
Myristic Acid SCHEMBL29634265 0.82 GPR84 (0.68) AKR1B1PPARGPPARDPPARAGPR84
Hexanoate SCHEMBL5013710 0.82 AKR1B1 (0.64) AKR1B1PPARGPPARDPPARAGPR84
Stearic Acid SCHEMBL16632630 0.82 GPR84 (0.68) AKR1B1PPARGPPARDPPARAGPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3969490-B1 MODIFIED HIGH-CIS POLYBUTADIENE POLYMER, RELATED METHODS AND TIRE COMPONENTS BRIDGESTONE CORP (JP) 2026-03-25 EP disclosed
US-20250389555-A1 MODIFIED HIGH-CIS POLYBUTADIENE POLYMER, RELATED METHODS AND RUBBER COMPOSITIONS BRIDGESTONE AMERICAS TIRE OPERATIONS, LLC (US) 2025-12-25 US disclosed
US-12479935-B2 Polymerization processes for the production of cis-1,4-polydienes BRIDGESTONE CORPORATION (JP) 2025-11-25 US disclosed
US-12410263-B2 Modified high-Cis polybutadiene polymer, related methods and rubber compositions BRIDGESTONE AMERICAS TIRE OPERATIONS, LLC (US) 2025-09-09 US disclosed
US-12371516-B2 Aged lanthanide-based catalyst systems and their use in the preparation of cis-1,4-polydienes BRIDGESTONE CORPORATION (JP) 2025-07-29 US disclosed
US-12264232-B2 Modified high-cis polybutadiene polymer, related methods and tire components BRIDGESTONE CORPORATION (JP) 2025-04-01 US disclosed
US-20250066516-A1 HYDROGENATED POLYBUTADIENE POLYMERS AND RUBBER COMPOSITIONS INCORPORATING SAME BRIDGESTONE CORPORATION (JP) 2025-02-27 US disclosed
EP-4495146-A2 MODIFIED HIGH-CIS POLYBUTADIENE POLYMER, RELATED METHODS AND RUBBER COMPOSITIONS Bridgestone Americas Tire Operations, LLC (US) 2025-01-22 EP disclosed
US-12168705-B2 Modified high cis polydiene polymer, related methods and rubber compositions BRIDGESTONE CORPORATION (JP) 2024-12-17 US disclosed
EP-4457250-A1 HYDROGENATED POLYBUTADIENE POLYMERS AND RUBBER COMPOSITIONS INCORPORATING SAME Bridgestone Corporation (JP) 2024-11-06 EP disclosed
EP-1242482-A1 IRON-BASED CATALYST FOR PRODUCING BINARY CIS-1,4-/1,2-POLYBUTADIENE Bridgestone Corporation (JP) 2002-09-25 EP disclosed
WO-2002068484-A1 CONTINUOUS PROCESS FOR THE PRODUCTION OF CONJUGATED DIENE POLYMERS HAVING NARROW MOLECULAR WEIGHT DISTRIBUTION AND PRODUCTS THEREFROM BRIDGESTONE CORPORATION (JP) 2002-09-06 WO disclosed
WO-2002066525-A1 CHROMIUM-BASED CATALYST COMPOSITION BRIDGESTONE CORPORATION (JP) 2002-08-29 WO disclosed
US-20020115558-A1 CHROMIUM-BASED CATALYST COMPOSITION FOR PRODUCING CONJUGATED DIENE POLYMERS BRIDGESTONE CORP. 2002-08-22 US disclosed
US-20020037967-A1 Process for producing blends of syndiotactic 1,2-polybutadiene and rubbery elastomers with a chromium-based catalyst system BRIDGESTONE CORPORATION (JP) 2002-03-28 US disclosed
US-6320004-B1 FORMED BY COMBINING (A) A IRON-CONTAINING COMPOUND; (B) AN ORGANOMAGNESIUM COMPOUND; AND (C) A SILYL PHOSPHONATE; POLYMERIZING CONJUGATED DIENE MONOMERS BRIDGESTONE CORPORATION (JP) 2001-11-20 US disclosed
WO-2001079309-A2 USE OF A Cr- OR Mo-BASED CATALYST SYSTEM TO PRODUCE BLENDS OF SYNDIOTACTIC 1,2-POLYBUTADIENE AND RUBBERY ELASTOMERS BRIDGESTONE CORPORATION (JP) 2001-10-25 WO disclosed
US-6291591-B1 PROVIDING MIXTURE OF RUBBER CEMENT AND 1,3-BUTADIENE; POLYMERIZING 1,3-BUTADIENE BY USING A CATALYST WHICH IS COMBINATION OF OR THE REACTION PRODUCT OF CHROMIUM COMPOUND, HYDROGEN PHOSPHITE, ORGANOMAGNESIUM COMPOUND BRIDGESTONE CORPORATION (JP) 2001-09-18 US disclosed
WO-2001049755-A1 IRON-BASED CATALYST FOR PRODUCING BINARY Cis-1,4-/1,2-POLYBUTADIENE BRIDGESTONE CORPORATION (JP) 2001-07-12 WO disclosed
US-6160063-A Iron-based catalyst for producing binary cis-1,4-/1,2-polybutadiene BRIDGESTONE CORPORATION (JP) 2000-12-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250389555-A1 MODIFIED HIGH-CIS POLYBUTADIENE POLYMER, RELATED METHODS AND RUBBER COMPOSITIONS MALT1, INO80C, RTCB AKR1B1 517/4885PPARG 3413/4885PPARD 4417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.